U.S. markets open in 2 hours 54 minutes

Sanofi (SNY)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
54.25+0.45 (+0.84%)
At close: 4:00PM EDT
Sign in to post a message.
  • N
    Nuno
    I think that sanofi in undervalued. From my calculations the target price is 93#$%$ however i'm not taking into consideration the molecules pipeline and assuming that dupixent dont lose market share.Please share your opinions.This post is not a recomendation.
    Bullish
  • d
    douglasg
    Today stock was starting to act as if appreciation is about to take this in some type of upward momentum. Great news, and bios with BIIB and MRNA leading the way.
    Bullish
  • S
    Slingshot
    BTX,GME,NVAX...jumping from single digit to double&triple degit....now its time for pfe,sny,xair to jump massive in the coming days and months
    Bullish
  • R
    Robot
    Does their new PR regarding their COVID vaccine with GSK include their work with Mymetics MYMX cold chain independent and virosome based vaccination platform, I know all have worked together in the past in this regard
  • S
    Slingshot
    I just cant understand, if small biotech company comes out with a drug approval then there stock rises to 50% to some times 300% increase but big biotech like pfe, sny or gsk comes out with FDA approvals, there sp increase is only 5% to 30% max, big biotech stockes are always 2digit or 3 digit but profits are always very less, hope that prespectives changes in the coming days, 2% to 5% devidend paying is not enough if the sp remains the same for months.
  • S
    Sektor
    Honest to god, Sanofi gave tbio 1.9 billion for it's vaccine for most likely variant only.

    which is where this all is going and headed.

    their is more, they put an awesome exec on tbio board

    wait there's more

    he got his option grants already so blast off getty up time as tbio should already be 100.00 a share, but 100.00 would not buy it

    tbio says no to that or sanofi raises against new bidder.

    sanofi handling both moderna and translate bio's vaccines

    do you see them handling vir cvac arct or vxrt srne btx ocgn

    of course not.

    buy a ton of may calls and you will see real quick these mm's do not like it.

    Sektor your teacher

    read more barrons and watch less cnbc soap opera, mad money or jimbo
  • S
    Sektor
    Tbio literally bought buy Sanofi at some price over 100.00 a share is Sektors hunch.

    Buddah the Magnificent crunched the numbers.

    Impossible to trade at just 1.6 billion market cap.

    vir and cvac, arct at around 5 billion, even garbage srne and ino vxrt with nothing trading even or over tbio.

    Tbio success is already set in stone and planned out.

    The horse Sanofi is going with in the Variant only and covi 2 is Translate.

    The same Translate lab Barron's weekly did a 4 page spread and declared tbio even with moderna.

    Now giant muscle pharma and one of the fastest delivering on final vaccine production in existentence.

    Tbio is a stock you park 200 grand in tomorrow

    the five nucklehead mm's in tbio are obviously holding tbio because only weak buyers have come in so far.

    Hammer the may calls. They don't like it and it makes them extremely nervous.

    India is only getting worse and worse.

    BV-1 is the one we dont want over here.

    India scientist are scared too death of that double mutation

    The said 7 to 10 days it will be basically unstoppable as it expertly rejects antibodies, with or without many proteins active.

    Covid is an eight year thing, if Tbio is wise enough to go to variant only which should have been done a year ago.

    Tbio is the next Moderna confirmed.

    Sanofi being allowed to handle both Moderna boosters and certainly most likely tbio translate bio variant only vaccines.

    Buddah that called 20 point pop off his scanner data at 18 says Mrs. Wood cometh to Tbio soon in a big day

    It will be the 35 point up day that cashes that put wall, expiring worthless.

    1.6 bill....Tbio worth 18 to 20 billion when they confirm variant onlys coming.

    They will sell in droves globally in 500k to 5 million run totals.

    Everytime these mm's get stupid and put an ultra tight bid ask spread on tbio, Sektor or Buddah is on the bid 20,000 shares at a time.

    Mm's already scared of the coming tbio pop, soon they have to let go of tbio for real, and not act like it, for an hour.

    Sektor your teacher

    sanofi is guarding over tbio like jackpot dinner or a tasty morcel meal.

    You think an offer comes in on tbio at 100.00 and Sanofi does not immediately raise over that, I have some bridges to sell you in mexico city..

    Sektor the Whale

    Where is your offer Sanofi. I hope someone comes in bidding 125 or 150 and you have to pay more than you like.

    It's what you deserve for allowing tbio to sit there and trade for nothing while confused robinhooders bid up trash like btx, ocugen, and vaxart.
  • S
    Slingshot
    Sanofi to open big multi vaccine manufacturing in Singapore as per local news, this is great news for Singapore and all investors....check the news feed about this info. Sanofi is the future of Bio Pharma manufactiring
  • J
    Jack
    Any opinion for today?
  • S
    Saint Preferred
    Article on Sanofi: "Vaccination combined with mask wearing, social distancing and more frequent handwashing imposed by the coronavirus crisis appear to have led to a drop in influenza contaminations in Europe this season."

    Those aren't facts at all. Somebody's opinion.
  • P
    PumpIt
    $ABIO conversation
    $ABIO Reddit buzz about this today. Lets go! #WSB #Reddit
    $PFE $SNY $EBS
  • C
    Cost
    I don't get what the scoop is with the price change on SNY today. My Merrill Edge AND Morningstar sites report a 2.83% decrease today (Monday May 3rd) but Yahoo Finance is saying it was up .84%. I know this is a ADR I hold here in the US and I also know the stock went ex-dividend today but regardless - I've never seen a discrepancy like this before. Can anyone explain this to me - if so - thanks.
    Bullish
  • S
    Saint Preferred
    "India sets fresh global case record, and US gears up to send oxygen, tests, treatments and PPE"

    Hahahahhahaha...Pompous propaganda....
  • W
    Wolf.of.BayStreet
    just got funding from canadian govt to build vaccine facility in toronto. heard it here first
  • M
    Madeleine
    Breaking : Ontario (CAN) to build vaccine facility
  • t
    trevorthegreat
    Thx for the cash, Sanofi. See you next year!!!!
    Bullish
  • s
    siggy
    $AGEN conversation
    $GSK $SNY covid19 vaccine #fails in #elderly group
    62.5% in the >60 age group
    will reformulate now
    they will need $AGEN #QS21 NOW FINALY for it too
    $GSK said back then they choose AS03 over #AS01 (QS21 adjuvant) due to missing manufacturing capabilities

    December 11, 2020 01:00 ET | Source: Sanofi
    multilang-release

    Sanofi and GSK announce a delay in their adjuvanted recombinant protein-based COVID-19 vaccine program to improve immune response in the elderly

    Phase 1/2 interim results showed an immune response comparable to patients who recovered from COVID-19 in adults aged 18 to 49 years
    Insufficient response in older adults demonstrates the need to refine the concentration of antigen in order to provide high-level immune response across all age groups
    Companies plan a Phase 2b study with an improved antigen formulation
    With support from BARDA as part of Operation Warp Speed, study to start in February 2021, including a proposed comparison with an authorized COVID-19 vaccine
    Product availability now expected in Q4 2021 pending successful completion of the development plan

    PARIS and LONDON – December 11, 2020 – Sanofi and GSK announce a delay in their adjuvanted recombinant protein-based COVID-19 vaccine program to improve immune response in older adults. Phase 1/2 study interim results showed an immune response comparable to patients who recovered from COVID-19 in adults aged 18 to 49 years, but a low immune response in older adults likely due to an insufficient concentration of the antigen.

    A recent challenge study in non-human primates performed with an improved antigen formulation demonstrated that the vaccine candidate could protect against lung pathology and lead to rapid viral clearance from the nasal passages and lungs, within 2 to 4 days. These results increase the Companies confidence in the capacity of the adjuvanted recombinant platform to deliver a highly efficient vaccine for all adults.

    Sanofi’s recombinant technology and GSK’s pandemic adjuvant are established vaccine platforms that have proven successful against influenza. The recombinant technology offers the advantages of stability at temperatures used for routine vaccines, the ability to generate high and sustained immune responses, and the potential to prevent virus transmission.

    “We care greatly about public health which is why we are disappointed by the delay announced today, but all our decisions are and will always be driven by science and data. We have identified the path forward and remain confident and committed to bringing a safe and efficacious COVID-19 vaccine. Following these results and the latest encouraging new preclinical data, we will now work to further optimize our candidate to achieve this goal,” said Thomas Triomphe, Executive Vice President and Head of Sanofi Pasteur. “No single pharma company can make it alone; the world needs more than one vaccine to fight the pandemic.”

    Roger Connor, President of GSK Vaccines added: “The results of the study are not as we hoped. Based on previous experience and other collaborations, we are confident that GSK’s pandemic adjuvant system, when coupled with a COVID-19 antigen, can elicit a robust immune response with an acceptable reactogenicity profile. It is also clear that multiple vaccines will be needed to contain the pandemic. Our aim now is to work closely with our partner Sanofi to develop this vaccine, with an improved antigen formulation, for it to make a meaningful contribution to preventing COVID-19.”

    The Companies plan a Phase 2b study expected to start in February 2021 with support from the Biomedical Advanced Research and Development Authority (BARDA), part of the HHS Office of the Assistant Secretary for Preparedness and Response (ASPR) under contract W15QKN-16-9-1002. The study will include a proposed comparison with an authorized COVID-19 vaccine. If data are positive, a global Phase 3 study could start in Q2 2021. Positive results from this study would lead to regulatory submissions in the second half of 2021, hence delaying the vaccine’s potential availability from mid-2021 to Q4 2021.

    Sanofi and GSK adjuvanted recombinant protein-based vaccine candidate was selected in July 2020 by U.S. government’s Operation Warp Speed in order to accelerate its development and manufacturing.

    The Companies have updated Governments and the European Commission where a contractual commitment to purchase the vaccine has been made.

    Phase 1/2 study

    The interim Phase 1/2 results showed a level of neutralizing antibody titers after two doses comparable to sera from patients who recovered from COVID-19, a balanced cellular response in adults aged 18 to 49 years, but insufficient neutralizing antibody titers in adults over the age of 50. The candidate showed transient but higher than expected levels of reactogenicity likely due to the suboptimal antigen formulation, with no serious adverse events related to the vaccine candidate.....
  • M
    Metal Ox
    $tbio Surprised appointment of $sny Sanofi exec did not move the share price needle. A positive development. Could signal tbio needs addtl exec to get organized, focused, or could signal higher level of coordination with Sanofi, or could hint at eventual buyout. In all cases positive. Anyone buying lots more on the news or is it more prudent to wait for stock to bottom and build new base?
  • M
    Momo
    $DVAX conversation
    $GSK $SNY covid19 vaccine #fails in #elderly group
    62.5% in the >60 age group
    Based on AS03 adjuvant ;-)

    December 11, 2020 01:00 ET | Source: Sanofi
    multilang-release

    Sanofi and GSK announce a delay in their adjuvanted recombinant protein-based COVID-19 vaccine program to improve immune response in the elderly

    Phase 1/2 interim results showed an immune response comparable to patients who recovered from COVID-19 in adults aged 18 to 49 years
    Insufficient response in older adults demonstrates the need to refine the concentration of antigen in order to provide high-level immune response across all age groups
    Companies plan a Phase 2b study with an improved antigen formulation
    With support from BARDA as part of Operation Warp Speed, study to start in February 2021, including a proposed comparison with an authorized COVID-19 vaccine
    Product availability now expected in Q4 2021 pending successful completion of the development plan

    PARIS and LONDON – December 11, 2020 – Sanofi and GSK announce a delay in their adjuvanted recombinant protein-based COVID-19 vaccine program to improve immune response in older adults. Phase 1/2 study interim results showed an immune response comparable to patients who recovered from COVID-19 in adults aged 18 to 49 years, but a low immune response in older adults likely due to an insufficient concentration of the antigen.

    A recent challenge study in non-human primates performed with an improved antigen formulation demonstrated that the vaccine candidate could protect against lung pathology and lead to rapid viral clearance from the nasal passages and lungs, within 2 to 4 days. These results increase the Companies confidence in the capacity of the adjuvanted recombinant platform to deliver a highly efficient vaccine for all adults.

    Sanofi’s recombinant technology and GSK’s pandemic adjuvant are established vaccine platforms that have proven successful against influenza. The recombinant technology offers the advantages of stability at temperatures used for routine vaccines, the ability to generate high and sustained immune responses, and the potential to prevent virus transmission.

    “We care greatly about public health which is why we are disappointed by the delay announced today, but all our decisions are and will always be driven by science and data. We have identified the path forward and remain confident and committed to bringing a safe and efficacious COVID-19 vaccine. Following these results and the latest encouraging new preclinical data, we will now work to further optimize our candidate to achieve this goal,” said Thomas Triomphe, Executive Vice President and Head of Sanofi Pasteur. “No single pharma company can make it alone; the world needs more than one vaccine to fight the pandemic.”

    Roger Connor, President of GSK Vaccines added: “The results of the study are not as we hoped. Based on previous experience and other collaborations, we are confident that GSK’s pandemic adjuvant system, when coupled with a COVID-19 antigen, can elicit a robust immune response with an acceptable reactogenicity profile. It is also clear that multiple vaccines will be needed to contain the pandemic. Our aim now is to work closely with our partner Sanofi to develop this vaccine, with an improved antigen formulation, for it to make a meaningful contribution to preventing COVID-19.”

    The Companies plan a Phase 2b study expected to start in February 2021 with support from the Biomedical Advanced Research and Development Authority (BARDA), part of the HHS Office of the Assistant Secretary for Preparedness and Response (ASPR) under contract W15QKN-16-9-1002. The study will include a proposed comparison with an authorized COVID-19 vaccine. If data are positive, a global Phase 3 study could start in Q2 2021. Positive results from this study would lead to regulatory submissions in the second half of 2021, hence delaying the vaccine’s potential availability from mid-2021 to Q4 2021.

    Sanofi and GSK adjuvanted recombinant protein-based vaccine candidate was selected in July 2020 by U.S. government’s Operation Warp Speed in order to accelerate its development and manufacturing.

    The Companies have updated Governments and the European Commission where a contractual commitment to purchase the vaccine has been made.

    Phase 1/2 study

    The interim Phase 1/2 results showed a level of neutralizing antibody titers after two doses comparable to sera from patients who recovered from COVID-19, a balanced cellular response in adults aged 18 to 49 years, but insufficient neutralizing antibody titers in adults over the age of 50. The candidate showed transient but higher than expected levels of reactogenicity likely due to the suboptimal antigen formulation, with no serious adverse events related to the vaccine candidate.....
  • D
    DaveM
    $CODX conversation
    Please IGNORE the lawsuits posted on yahoo...they have no merit and should not have effect on CODX...been through all this with INO...do your due diligence and read up on INO message board
    THE MESSAGE
    Citron Research Analyst made a Short-Selling SEC 72 Hour news or subjective comment and brought huge block-trade short-selling traders, alert that the SEC should have halted all Short-Sellers, because of the Twitter Tweet can be considered a volatile statement, in that, the legal class action suits should have been filed against Citron Research for their false claims made against Inovio $INO, in a deliberate act of causing significant shareholder losses due to their Tweet sent, March 9, 2020.
    By James Gornick
    Wednesday, April 22, 2020 11:10 AM EDT
    Currently, we have price targets for $INO PT’s near-term and long-term. The near-term PT is $37-$48 dollars a share. The longer-term price-target is between $72 - $98 dollars a share in the 2020-2021 fiscal reporting quarters. We make these PT’s based on Inovio huge pipeline of candidates for FDA approvals over these next two years or less.
    FURTHER FACTS AGANIST CITRON AND FILED CLASS-ACTION EFFORTS
    Where are the Twitter Tweets of the law firms filing or that Citron subjective feelings on the GlaxoSmithKline and Sanofi? They are certainly missing their Tweets on $GSK and $SNY as maybe a short-selling candidate’s as Citron had chosen Inovio $INO in their development of a vaccine in a 3 hour start-up period. Remember, INO-4700 was already in active Phase 1 / 2 trials during Summer 2019. The tweaking and following FDA guidelines as well as W.H.O.guidlines with INO-4800 before applying for FDA approvals as clearly stated by Dr. Kim, CEO of Inovio Pharmaceuticals. Make no mistake, we still don't agree with the further delusion of shareholder value by the newest agreement by Inovio and Stifel Nicholas 150 million share offer but know they can use these proceeds for bringing their robust drug pipeline to final market with FDA approvals.
    WHAT'S THE FINAL TRADING MESSAGE
    Time to send the message for the Institutional Investors to run back into ownership--long positions, and bring the bullish goring of the short-selling bears on $INO to break their trading funds within their banks...